Diagnóstico de cáncer de próstata posterior a tratamiento antibiótico en pacientes con antígeno prostático específico entre 4 y 10 ng/ml

Autores:: Infantes Burgos, Ronald Javier
Maciá Carrasquilla, Juan Alonso
Ramos Clason, Enrique Carlos

Tipo de recurso:: Article of journal

Fecha de publicación:: 2014

Institución:: Universidad de Cartagena

Repositorio:: Repositorio Universidad de Cartagena

Idioma:: spa

id	UCART2_53b1f4c9e75f58b31da1f4c8e6cbcdba
oai_identifier_str	oai:repositorio.unicartagena.edu.co:11227/13104
network_acronym_str	UCART2
network_name_str	Repositorio Universidad de Cartagena
repository_id_str
dc.title.spa.fl_str_mv	Diagnóstico de cáncer de próstata posterior a tratamiento antibiótico en pacientes con antígeno prostático específico entre 4 y 10 ng/ml
dc.title.translated.eng.fl_str_mv	Diagnóstico de cáncer de próstata posterior a tratamiento antibiótico en pacientes con antígeno prostático específico entre 4 y 10 ng/ml
title	Diagnóstico de cáncer de próstata posterior a tratamiento antibiótico en pacientes con antígeno prostático específico entre 4 y 10 ng/ml
spellingShingle	Diagnóstico de cáncer de próstata posterior a tratamiento antibiótico en pacientes con antígeno prostático específico entre 4 y 10 ng/ml Neoplasias de la próstata Antígeno prostático específico Próstata.
title_short	Diagnóstico de cáncer de próstata posterior a tratamiento antibiótico en pacientes con antígeno prostático específico entre 4 y 10 ng/ml
title_full	Diagnóstico de cáncer de próstata posterior a tratamiento antibiótico en pacientes con antígeno prostático específico entre 4 y 10 ng/ml
title_fullStr	Diagnóstico de cáncer de próstata posterior a tratamiento antibiótico en pacientes con antígeno prostático específico entre 4 y 10 ng/ml
title_full_unstemmed	Diagnóstico de cáncer de próstata posterior a tratamiento antibiótico en pacientes con antígeno prostático específico entre 4 y 10 ng/ml
title_sort	Diagnóstico de cáncer de próstata posterior a tratamiento antibiótico en pacientes con antígeno prostático específico entre 4 y 10 ng/ml
dc.creator.fl_str_mv	Infantes Burgos, Ronald Javier Maciá Carrasquilla, Juan Alonso Ramos Clason, Enrique Carlos
dc.contributor.author.spa.fl_str_mv	Infantes Burgos, Ronald Javier Maciá Carrasquilla, Juan Alonso Ramos Clason, Enrique Carlos
dc.subject.spa.fl_str_mv	Neoplasias de la próstata Antígeno prostático específico Próstata.
topic	Neoplasias de la próstata Antígeno prostático específico Próstata.
publishDate	2014
dc.date.accessioned.none.fl_str_mv	2014-01-15 00:00:00
dc.date.available.none.fl_str_mv	2014-01-15 00:00:00
dc.date.issued.none.fl_str_mv	2014-01-15
dc.type.spa.fl_str_mv	Artículo de revista
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.version.spa.fl_str_mv	info:eu-repo/semantics/publishedVersion
dc.type.coarversion.spa.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.spa.fl_str_mv	http://purl.org/coar/resource_type/c_6501
dc.type.content.spa.fl_str_mv	Text
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/article
dc.type.local.eng.fl_str_mv	Journal article
format	http://purl.org/coar/resource_type/c_6501
status_str	publishedVersion
dc.identifier.issn.none.fl_str_mv	2215-7840
dc.identifier.uri.none.fl_str_mv	https://hdl.handle.net/11227/13104
dc.identifier.doi.none.fl_str_mv	10.32997/rcb-2014-2885
dc.identifier.eissn.none.fl_str_mv	2389-7252
dc.identifier.url.none.fl_str_mv	https://doi.org/10.32997/rcb-2014-2885
identifier_str_mv	2215-7840 10.32997/rcb-2014-2885 2389-7252
url	https://hdl.handle.net/11227/13104 https://doi.org/10.32997/rcb-2014-2885
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.ispartofjournal.spa.fl_str_mv	Revista Ciencias Biomédicas
dc.relation.bitstream.none.fl_str_mv	https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/2885/2428
dc.relation.citationedition.spa.fl_str_mv	Núm. 1 , Año 2014
dc.relation.citationendpage.none.fl_str_mv	40
dc.relation.citationissue.spa.fl_str_mv	1
dc.relation.citationstartpage.none.fl_str_mv	35
dc.relation.citationvolume.spa.fl_str_mv	5
dc.relation.references.spa.fl_str_mv	Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991;145(5):907-923. Catalona WJ, Ramos CG, Carvalhal GF, Yan Y. Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology. 2000;55(6):791-795. Gilbert SM, Cavallo CB, Kahane H, Lowe FC. Evidence suggesting PSA cut point of 2.5 ng/Ml for prompting prostate biopsy: review of 36,316 biopsies. Urology. 2005;65(3):549-553. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 1995;154(2):407-413. Carver BS, Bozeman CB, Williams BJ, Venable DD. The prevalence of men with National Institutes of Health category IV prostatitis and association with serum prostate specific antigen. J Urol. 2003;169(2):589-591. Karazanashvili G, Managadze L. Prostate-specificanti gen (PSA) value change after antibacterial therapy of prostate inflammation, as a diagnostic method for prostate cancer screening in cases of PSA value within 4–10 ng/ml and nonsuspicious results of digital rectal examination. Eur Urol. 2001;39:538-543. Stancik I, Luftenegger W, Klimpfinger M. Muller MM, Hoeltl W. Effect of NIH-IV prostatitis on free and free-to-total PSA. Eur Urol. 2004;46(6)760-764. Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA.1999;282(3):236-246. Schaeffer AJ, Wu SC, Tennenberg AM, Kahn JB. Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. J Urol. 2005;174(1):161-164. Sheikh M, Al-Saeed O, Kehinde EO, Sinan T, Anim JT, Ali Y. Utility of volume adjusted prostate specific antigen density in the diagnosis of prostate cancer in Arab men. Int Urol Nephrol. 2005;37(4):721-726. Yaman O, Gogus C, Tulunay O, et al. Increased prostate-specific antigen in subclínical prostatitis: the role of aggressiveness and extension of inflammation. Urol Int. 2003;71:160-164. Ozden C, Inal G, Adsan O, Yazici S, Ozturk B, Cetinkaya M. Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA. Urol Int. 2003;71(2):150-153. Okada K, Kojima M, Naya Y, Kamoi K, Yokoyama K, Takamatsu T, Miki T. Correlation of histological inflammation in needle biopsy specimens with serum prostate-specific antigen levels in men with negative biopsy for prostate cancer. Urology. 2000;55(6):892-898. Gümüş BH, Neşe N, Gündüz MI, Kandiloglu AR, Ceylan Y, Büyüksu C. Does asymptomatic inflammation increase PSA? A histopathological study comparing benign and malignant tissue biopsy specimens. Int Urol Nephrol. 2004;36(4):549-553. Kobayashi M, Nukui A, Morita T. Serum PSA and percent free PSA value changes after antibiotic treatment. A diagnostic method in prostate cancer suspects with asymptomatic prostatitis. Urol Int. 2008;80(2):186-192. Kim YJ, Kim SO, Ryu KH, Hwang IS, Hwang EC, Oh KJ, et al. Prostate cancer can be detected even in patients with decreased PSA less than 2.5 ng/ml after treatment of chronic prostatitis. Korean J Urol. 2011;52(7):457-460. Tang P, Xie KJ, Wang B, Deng XR, Ou RB. Antibacterial therapy improves the effectiveness of prostate cancer detection using prostate-specific antigen in patients with asymptomatic prostatitis. Int Urol Nephrol. 2010;42(1):13–18. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA. 1997;277(18):1452-1455. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998;279(19):1542-1547. Lodding P, Aus G, Bergdahl S, Frösing R, Lilja H, Pihl CG, Hugosson J. Characteristics of screening detected Prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen. J Urol. 1998;159(3):899-903. Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman CC, Marberger M. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol. 2000;163(4):1144-1149. Babaian RJ. Extended field prostate biopsy enhances cancer detection. Urology. 2000;55(4):453-456. Babaian RJ, Johnston DA, Naccarato W, Ayala A, Bhadkamkar VA, Fritsche HA. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng./ml: relation to biopsy strategy. J Urol. 2001;165:757-760.
dc.rights.spa.fl_str_mv	Revista Ciencias Biomédicas - 2020
dc.rights.uri.spa.fl_str_mv	https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.coar.spa.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	Revista Ciencias Biomédicas - 2020 https://creativecommons.org/licenses/by-nc-sa/4.0/ http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.publisher.spa.fl_str_mv	Universidad de Cartagena
dc.source.spa.fl_str_mv	https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/2885
institution	Universidad de Cartagena
bitstream.url.fl_str_mv	https://repositorio.unicartagena.edu.co/bitstream/11227/13104/1/ORE.xml
bitstream.checksum.fl_str_mv	7d33e052ca78fdbda94bae5ec779d7a5
bitstream.checksumAlgorithm.fl_str_mv	MD5
repository.name.fl_str_mv	Biblioteca Digital Universidad de Cartagena
repository.mail.fl_str_mv	bdigital@metabiblioteca.com
_version_	1808418234218577920
spelling	Infantes Burgos, Ronald Javier60bb470650d6b1c99101a4c03f9e37d9Maciá Carrasquilla, Juan Alonsof5e8799ce651f4da5315c5b77528c8e3Ramos Clason, Enrique Carlos310021cec34c38f298424686141e077c5002014-01-15 00:00:002014-01-15 00:00:002014-01-152215-7840https://hdl.handle.net/11227/1310410.32997/rcb-2014-28852389-7252https://doi.org/10.32997/rcb-2014-2885application/pdfspaUniversidad de CartagenaRevista Ciencias Biomédicashttps://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/2885/2428Núm. 1 , Año 2014401355Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991;145(5):907-923.Catalona WJ, Ramos CG, Carvalhal GF, Yan Y. Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology. 2000;55(6):791-795.Gilbert SM, Cavallo CB, Kahane H, Lowe FC. Evidence suggesting PSA cut point of 2.5 ng/Ml for prompting prostate biopsy: review of 36,316 biopsies. Urology. 2005;65(3):549-553.Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 1995;154(2):407-413.Carver BS, Bozeman CB, Williams BJ, Venable DD. The prevalence of men with National Institutes of Health category IV prostatitis and association with serum prostate specific antigen. J Urol. 2003;169(2):589-591.Karazanashvili G, Managadze L. Prostate-specificanti gen (PSA) value change after antibacterial therapy of prostate inflammation, as a diagnostic method for prostate cancer screening in cases of PSA value within 4–10 ng/ml and nonsuspicious results of digital rectal examination. Eur Urol. 2001;39:538-543.Stancik I, Luftenegger W, Klimpfinger M. Muller MM, Hoeltl W. Effect of NIH-IV prostatitis on free and free-to-total PSA. Eur Urol. 2004;46(6)760-764.Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA.1999;282(3):236-246.Schaeffer AJ, Wu SC, Tennenberg AM, Kahn JB. Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. J Urol. 2005;174(1):161-164.Sheikh M, Al-Saeed O, Kehinde EO, Sinan T, Anim JT, Ali Y. Utility of volume adjusted prostate specific antigen density in the diagnosis of prostate cancer in Arab men. Int Urol Nephrol. 2005;37(4):721-726.Yaman O, Gogus C, Tulunay O, et al. Increased prostate-specific antigen in subclínical prostatitis: the role of aggressiveness and extension of inflammation. Urol Int. 2003;71:160-164.Ozden C, Inal G, Adsan O, Yazici S, Ozturk B, Cetinkaya M. Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA. Urol Int. 2003;71(2):150-153.Okada K, Kojima M, Naya Y, Kamoi K, Yokoyama K, Takamatsu T, Miki T. Correlation of histological inflammation in needle biopsy specimens with serum prostate-specific antigen levels in men with negative biopsy for prostate cancer. Urology. 2000;55(6):892-898.Gümüş BH, Neşe N, Gündüz MI, Kandiloglu AR, Ceylan Y, Büyüksu C. Does asymptomatic inflammation increase PSA? A histopathological study comparing benign and malignant tissue biopsy specimens. Int Urol Nephrol. 2004;36(4):549-553.Kobayashi M, Nukui A, Morita T. Serum PSA and percent free PSA value changes after antibiotic treatment. A diagnostic method in prostate cancer suspects with asymptomatic prostatitis. Urol Int. 2008;80(2):186-192.Kim YJ, Kim SO, Ryu KH, Hwang IS, Hwang EC, Oh KJ, et al. Prostate cancer can be detected even in patients with decreased PSA less than 2.5 ng/ml after treatment of chronic prostatitis. Korean J Urol. 2011;52(7):457-460.Tang P, Xie KJ, Wang B, Deng XR, Ou RB. Antibacterial therapy improves the effectiveness of prostate cancer detection using prostate-specific antigen in patients with asymptomatic prostatitis. Int Urol Nephrol. 2010;42(1):13–18.Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA. 1997;277(18):1452-1455.Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998;279(19):1542-1547.Lodding P, Aus G, Bergdahl S, Frösing R, Lilja H, Pihl CG, Hugosson J. Characteristics of screening detected Prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen. J Urol. 1998;159(3):899-903.Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman CC, Marberger M. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol. 2000;163(4):1144-1149.Babaian RJ. Extended field prostate biopsy enhances cancer detection. Urology. 2000;55(4):453-456.Babaian RJ, Johnston DA, Naccarato W, Ayala A, Bhadkamkar VA, Fritsche HA. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng./ml: relation to biopsy strategy. J Urol. 2001;165:757-760.Revista Ciencias Biomédicas - 2020https://creativecommons.org/licenses/by-nc-sa/4.0/http://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccesshttps://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/2885Neoplasias de la próstataAntígeno prostático específicoPróstata.Diagnóstico de cáncer de próstata posterior a tratamiento antibiótico en pacientes con antígeno prostático específico entre 4 y 10 ng/mlDiagnóstico de cáncer de próstata posterior a tratamiento antibiótico en pacientes con antígeno prostático específico entre 4 y 10 ng/mlArtículo de revistainfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articleJournal articleOREORE.xmltext/xml2662https://repositorio.unicartagena.edu.co/bitstream/11227/13104/1/ORE.xml7d33e052ca78fdbda94bae5ec779d7a5MD51open access11227/13104oai:repositorio.unicartagena.edu.co:11227/131042023-06-13 14:23:23.455An error occurred on the license name.\|\|\|https://creativecommons.org/licenses/by-nc-sa/4.0/metadata only accessBiblioteca Digital Universidad de Cartagenabdigital@metabiblioteca.com

Diagnóstico de cáncer de próstata posterior a tratamiento antibiótico en pacientes con antígeno prostático específico entre 4 y 10 ng/ml

Publicaciones similares